Publications by authors named "Nick Thatcher"

Claim this Profile
T
Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Michael Thomas, Nick Thatcher, Jerome Goldschmidt, Yuichiro Ohe, Helen J McBride

Immunotherapy· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Martin Reck, Keith M Kerr, Christian Grohé, Christian Manegold, Nick Pavlakis, Nick Thatcher

Future Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Cesare Gridelli, Javier de Castro Carpeno, Anne-Marie C Dingemans, Frank Griesinger, Francesco Grossi, Nick Thatcher

JAMA Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
Fred R Hirsch, Keith M Kerr, Paul A Bunn, Edward S Kim, Coleman Obasaju, Nick Thatcher

Clin Lung Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.
Kelvin Young, Luis Paz-Ares, Nick Thatcher, David R Spigel, Javad Shahidi

Thromb Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Tudor Ciuleanu, Mark A Socinski, Coleman Obasaju, Alexander V Luft, Aleksandra Szczesna, Nick Thatcher

Clin Lung Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
Carlo Genova, Mark A Socinski, Rebecca R Hozak, Gu Mi, Raffael Kurek, Nick Thatcher

J Thorac Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
Mark A Socinski, Coleman Obasaju, David Gandara, Fred R Hirsch, Philip Bonomi, Nick Thatcher

J Thorac Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A Socinski, Nick Thatcher

Oncol Res Treat· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
Corey J Langer, Coleman Obasaju, Paul Bunn, Philip Bonomi, David Gandara, Nick Thatcher

J Thorac Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic Features of Advanced Squamous NSCLC.
Mark A Socinski, Coleman Obasaju, David Gandara, Fred R Hirsch, Philip Bonomi, Nick Thatcher

J Thorac Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
Martin Reck, Mark A Socinski, Alexander Luft, Aleksandra Szczęsna, Mircea Dediu, Nick Thatcher

J Thorac Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Nick Thatcher, Fred R Hirsch, Alexander V Luft, Aleksandra Szczesna, Tudor E Ciuleanu

Lancet Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Luis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, Jürgen R Fischer, Joachim von Pawel, Nick Thatcher

Lancet Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
Jean-Louis Pujol, Robert Pirker, Thomas J Lynch, Charles A Butts, Rafael Rosell, Nick Thatcher

Lung Cancer· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Charles Butts, Mark A Socinski, Paul L Mitchell, Nick Thatcher, Libor Havel

Lancet Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor inhibition in lung cancer: status 2012.
Fred R Hirsch, Pasi A Jänne, Wilfried E Eberhardt, Federico Cappuzzo, Nick Thatcher

J Thorac Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.
Fiona Blackhall, Nick Thatcher, Richard Booton, Keith Kerr

Lung Cancer· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Martin Reck, Nick Thatcher, Egbert F Smit, Paul Lorigan, Ewa Szutowicz-Zielinska

Lung Cancer· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Giorgio Scagliotti, Rolf A Stahel, Rafael Rosell, Nick Thatcher, Jean-Charles Soria

Eur J Cancer· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Cesare Gridelli, Jaafar Bennouna, Javier de Castro, Anne-Marie C Dingemans, Frank Griesinger, Nick Thatcher

Clin Lung Cancer· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Raffaele Califano, Richard Griffiths, Paul Lorigan, Linda Ashcroft, Paul Taylor, Nick Thatcher

Lung Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
Håkan Mellstedt, Johan Vansteenkiste, Nick Thatcher

Lung Cancer· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Lucio Crinò, Eric Dansin, Pilar Garrido, Frank Griesinger, Janessa Laskin, Nick Thatcher

Lancet Oncol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Fiona H Blackhall, Mary O'brien, Peter Schmid, Marianne Nicolson, Paul Taylor, Nick Thatcher

J Thorac Oncol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis